You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, Follicular

Showing 51 - 75 of 6,008
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma Trial in Boston (Rituximab, Neo Vax, Pembrolizumab)

Recruiting
  • Follicular Lymphoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2022

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +12 more
  • Tucson, Arizona
    The University of Arizona Cancer Center
Dec 13, 2022

B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

Recruiting
  • B Cell Lymphoma
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 3, 2023

Follicular Lymphoma Trial in Toronto (12 Gy in 6 daily fractions)

Recruiting
  • Follicular Lymphoma
  • 12 Gy in 6 daily fractions
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
Mar 10, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Adult Patients Who Initiate Systemic Treatment for Relapsed or

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Non-Interventional
  • Graz, Austria
  • +8 more
Sep 19, 2022

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +3 more
  • Clinical Observation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

Recruiting
  • Follicular Lymphoma
  • Relapsed and Refractory Follicular Lymphoma
  • Guangzhou, Guangdong, China
  • +2 more
Mar 23, 2022

Follicular Lymphoma Trial in United States (DRL_RI (Proposed rituximab biosimilar), MabThera®)

Active, not recruiting
  • Follicular Lymphoma
  • DRL_RI (Proposed rituximab biosimilar)
  • MabThera®
  • Whittier, California
  • +3 more
May 27, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

DLBCL, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in New Haven, Worcester, Dallas (ABBV-319)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Aug 22, 2022

Follicular Lymphoma Trial in Boston (Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells)

Active, not recruiting
  • Follicular Lymphoma
  • Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Feb 28, 2022

Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Follicular Lymphoma
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Lentiviral-based Gene-edited Immune Cell Therapy

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • Pell's lentiviral-based gene-edited immune cell therapy
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

Follicular Lymphoma Trial in United States (Rituximab, Utomilumab, Avelumab)

Active, not recruiting
  • Follicular Lymphoma
  • Duarte, California
  • +5 more
Mar 17, 2022

Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide,

Recruiting
  • Follicular Lymphoma and Marginal Zone Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
  • lenalinomide
  • Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Feb 13, 2022

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in United Kingdom (Epcoritamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Aberdeen, United Kingdom
  • +24 more
Apr 28, 2023

Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • CD19-targeted chimeric antigen receptor T-cell
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in

Not yet recruiting
  • Follicular Lymphoma
  • Cellular immunity vs SARS-CoV-2
  • +6 more
  • Alessandria, IT, Italy
  • +13 more
Oct 10, 2023

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022